BlackRock Inc. grew its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,568,159 shares of the biopharmaceutical company’s stock after acquiring an additional 106,228 shares during the period. BlackRock Inc. owned 0.10% of Vanda Pharmaceuticals worth $69,436,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in VNDA. Teacher Retirement System of Texas bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $209,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Vanda Pharmaceuticals during the third quarter worth approximately $277,000. Cubist Systematic Strategies LLC raised its stake in shares of Vanda Pharmaceuticals by 221.3% during the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 17,485 shares during the last quarter. Strs Ohio raised its stake in shares of Vanda Pharmaceuticals by 27.4% during the fourth quarter. Strs Ohio now owns 56,200 shares of the biopharmaceutical company’s stock worth $854,000 after buying an additional 12,100 shares during the last quarter. Finally, Cadence Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the third quarter worth approximately $1,121,000. 81.04% of the stock is owned by institutional investors.
In other Vanda Pharmaceuticals news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the sale, the insider now owns 1,031,848 shares of the company’s stock, valued at $15,787,274.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total transaction of $130,747.68. Following the completion of the sale, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The disclosure for this sale can be found here. Insiders sold 287,506 shares of company stock valued at $4,665,795 in the last ninety days. Insiders own 7.60% of the company’s stock.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. The firm had revenue of $44.28 million during the quarter, compared to the consensus estimate of $44.00 million. During the same quarter in the prior year, the firm earned $0.08 earnings per share. The business’s quarterly revenue was up 15.8% on a year-over-year basis. equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -0.13 EPS for the current fiscal year.
A number of equities research analysts recently weighed in on VNDA shares. Oppenheimer reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 8th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Jefferies Group reissued a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 13th. Finally, Seaport Global Securities started coverage on shares of Vanda Pharmaceuticals in a research note on Friday, January 19th. They set a “buy” rating and a $20.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $21.57.
TRADEMARK VIOLATION NOTICE: This article was posted by WKRB News and is the property of of WKRB News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.wkrb13.com/2018/04/02/vanda-pharmaceuticals-inc-vnda-shares-bought-by-blackrock-inc.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.